IGM Biosciences
IGM Biosciences is a biotechnology company focused on developing engineered IgM antibodies for treating cancer and autoimmune and inflammatory diseases, with a robust pipeline and a dedicated manufacturing facility in Mountain View, CA.
Company Overview
IGM Biosciences is pioneering a new class of antibody medicines aimed at treating cancer and autoimmune and inflammatory diseases. The company focuses on developing engineered therapeutic IgM antibodies, known for their greater binding power compared to the more commonly used IgG antibodies. With a strong pipeline targeting critical health conditions, IGM Biosciences positions itself as a leader in innovative medical treatments.
Pipeline of Therapies
IGM Biosciences has a robust pipeline of therapies specifically targeting cancer and autoimmune and inflammatory diseases. Notable developments include Aplitabart, an IgM antibody targeting death receptor 5 (DR5) currently in Phase 1 combination trials for colorectal cancer, and Imvotamab, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 in Phase 1b clinical trials for severe systemic lupus erythematosus and rheumatoid arthritis. Additionally, IGM-2644, another bispecific T cell engaging IgM antibody, is being developed for the treatment of autoimmune diseases.
Expanded Access Program
IGM Biosciences offers an Individual Patient Expanded Access (IPEA) program aimed at patients with serious or life-threatening diseases who are not eligible for clinical trials. This initiative allows patients to gain access to investigational therapies outside of standard clinical development pathways, underscoring the company's commitment to addressing urgent medical needs.
GMP Manufacturing Facility
IGM Biosciences operates a dedicated GMP manufacturing facility in Mountain View, CA, for the production of their engineered IgM antibodies. This facility is crucial for ensuring the high standards required for clinical and eventual commercial use, emphasizing the company’s commitment to quality and reliability in their therapeutic products.